This episode discusses patient priorities in primary biliary cholangitis.

The management of abnormal liver blood tests has traditionally been the focus of many clinicians and industry work in this area. However, it is known that some patients have a significant symptom burden, particularly from itch, cognitive symptoms, and fatigue. The community now recognises that both biochemical improvement and symptom management are of equal importance and this must be reflected in clinical practice and research agenda.


  • Jessica Dyson (Moderator)
  • Alexander Artyomenko (IPSEN Representative)
  • Stuart Kendrick (GSK Representative)
  • Robert Mitchell-Thain (PBC Foundation Representative)
  • Pam Vig (Mirum Pharmaceuticals Representative)

This episode was scheduled according to the international calendar for the Primary Biliary Cholangitis Awareness Month.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

This EASL Studio is supported by CymaBay Therapeutics, GSK, IPSEN, and Mirum Pharmaceuticals.

Log in to post comments